Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wild-type adeno-associated virus-like particles (wtAAVLPs) are non-infectious, DNA-free protein shells derived from Adeno-associated virus serotype 2 (AAV2). These particles are assembled from the major capsid protein VP3 with the assistance of the assembly-activating protein (AAP), forming a stable 25-nm icosahedral structure. Unlike recombinant AAV vectors, wtAAVLPs lack a viral genome and are incapable of gene transfer. They serve as a highly immunogenic scaffold for vaccine development, where foreign epitopes can be inserted into specific capsid positions (such as 453 or 587) to elicit potent B-cell responses. In research contexts, wtAAVLPs are used as negative controls or as the baseline platform for chimeric vaccines targeting pathogens like Human Papillomavirus (HPV). The platform is noted for its stability, which allows for lyophilization and storage without a cold chain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on wild-type adeno-associated virus-like particle.